Washington Post: Rare but Serious Risks of Ozempic and Other GLP-1 Drugs
On November 16, 2026, The Washington Post published an in-depth look at the risks of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound. For millions of patients, the reporters note, the drugs have been safe and effective. But with so many people taking them, rare and serious problems, including sudden vision loss and severe stomach injuries, are coming to light.
The Post reports that thousands of patients are now suing Novo Nordisk and Eli Lilly, alleging they were not adequately warned. These Ozempic and GLP-1 lawsuits are now consolidated in federal court. The companies maintain that their products are safe.
Ozempic and Vision Loss: One Patient’s Story
The article centers on a 63-year-old Maryland man who lost vision in one eye four months after starting Ozempic for diabetes, and later in the other eye. He is now legally blind.
“If anyone had told me there’s a possibility that this could happen, there is just no way that I would ever take that medication,” he told the Post.
What Is NAION, the “Eye Stroke” Under Study in GLP-1 Users?
NAION (non-arteritic anterior ischemic optic neuropathy) is a sudden loss of blood flow to the optic nerve, often called an “eye stroke.” The Post describes the growing evidence connecting it to semaglutide, the active ingredient in Ozempic and Wegovy:
- A March 2026 study of more than 100,000 U.S. veterans found that semaglutide users had roughly twice the risk of NAION as patients starting a different common diabetes drug.
- Earlier this month, the U.S. Food and Drug Administration required the makers of GLP-1 drugs to add safety labeling about a potentially higher risk of NAION.
- European regulators had already classified NAION as a very rare side effect of semaglutide.
Severe Stomach Problems: Gastroparesis, Ileus, and Bowel Obstruction
According to the Post, most cases involve severe gastrointestinal injuries, while the list of potential complications under study is growing.
Read the full article at The Washington Post.
Where the Ozempic and GLP-1 Lawsuits Stand
These questions are at the center of two federal multidistrict litigations (MDLs). In an MDL, similar cases from across the country are brought before one judge for pretrial proceedings. Both GLP-1 MDLs are in the U.S. District Court for the Eastern District of Pennsylvania, and Wagstaff & Cartmell Managing Partner Sarah Ruane serves as Co-Lead Counsel in each.
Gastrointestinal injuries, MDL No. 3094. These cases claim that GLP-1 drugs can cause gastroparesis, a condition in which the stomach empties abnormally slowly, as well as ileus and bowel obstruction. Sarah was appointed Co-Lead Counsel in the Ozempic MDL in May 2024.
Vision loss, MDL No. 3163. These cases claim that GLP-1 drugs can cause NAION and permanent vision loss. Sarah was appointed Co-Lead Counsel in February 2026.
As Co-Lead Counsel, Sarah works with co-lead counsel from other firms to direct the litigation on behalf of all plaintiffs in each MDL, including discovery, expert evidence, and preparation for trial. The GLP-1 cases are part of the firm’s broader mass actions and personal injury practice, which has a track record in national pharmaceutical and medical device litigation.
Frequently Asked Questions About GLP-1 Lawsuits
Can Ozempic cause blindness? The Post describes evidence connecting semaglutide to NAION, a sudden loss of blood flow to the optic nerve that can cause permanent vision loss. A March 2026 study found roughly twice the risk among semaglutide users, and the FDA has required new labeling about a potentially higher risk. The cases in MDL No. 3163 claim GLP-1 drugs can cause NAION and permanent vision loss.
Which drugs are involved in the GLP-1 lawsuits? The Post’s reporting covers GLP-1 drugs including Ozempic, Wegovy, Mounjaro, and Zepbound, made by Novo Nordisk and Eli Lilly.
What injuries are the lawsuits about? MDL No. 3094 involves gastroparesis, ileus, and bowel obstruction. MDL No. 3163 involves NAION and permanent vision loss.
What is an MDL? A multidistrict litigation brings similar cases from across the country before one federal judge for pretrial proceedings. Both GLP-1 MDLs are in the Eastern District of Pennsylvania.
Talk to a GLP-1 Lawyer
If you or a family member took a GLP-1 drug and developed severe stomach problems or sudden vision loss, we will review your situation. Contact us.
Attorneys with clients who may have a GLP-1 claim can learn more about working with us. Learn more.
Related reading: Ozempic and Wegovy Lawsuits · Sarah Ruane Named to Lawdragon 100 Managing Partners You Need to Know · Medtronic MiniMed Insulin Pump Recall